血管内皮细胞生长因子在急性肺损伤中的表达及作用机制
|
摘要
第一部分血管内皮细胞生长因子在急性肺损伤中的表达
目的探讨脂多糖(LPS)吸入导致急性肺损伤(ALI)模型中血管内皮细胞生长因子(VEGF)表达的变化情况及其与肺损伤程度的关系。方法将30只雄性BALB/c小鼠随机分为6组(n=5),分别为LPS 4h组、LPS 24h组、LPS 48h组、PBS 4h组、PBS 24h组和PBS 48h组,麻醉后行气管内插管,LPS组吸入LPS (3mg/kg), PBS组吸入等容量磷酸盐缓冲液(PBS)作为对照。在预定的时间点(4h,24h,48h)左心室穿刺,行血气分析；保留血浆检测VEGF水平；肺泡灌洗液(BALF)检测VEGF水平和蛋白定量；留取肺组织行病理学检测、免疫组化检测以及实时定量PCR检测VEGF mRNA表达水平。结果与PBS各组相比,LPS组均出现明显的肺损伤改变,其中LPS 24h组的病理变化最为明显,肺损伤评分显著增加(1.5 vs 12,P<0.001)；与PBS 24h组相比：LPS 24h组出现明显低氧血症(97.27±8.96 mmHg vs 64.24±10.53 mmHg, P<0.001)、二氧化碳潴留(37.83±5.75 mmHg vs 49.00±9.19 mmHg, P< 0.05)和酸中毒(7.42±0.07 vs 7.17±0.05, P< 0.001); BALF中蛋白定量(183.28±15.58μg/ml vs 569.17±114.68μg/ml, P<0.05)和VEGF(32.45±6.57 pg/ml vs 160.14±34.25 pg/ml, P<0.05)均明显增加,且二者呈正相关(r=0.676,P<0.001)；血浆(12.44±4.05 pg/ml vs 31.53±1.96 pg/ml, P<0.05)和肺组织中VEGF升高,肺组织中VEGF mRNA表达也升高(0.24±0.07 vs 0.55±0.10,P<0.05)。结论LPS吸入成功地建立了ALI模型,ALI模型的血浆、肺组织和BALF中VEGF水平明显升高,BALF中蛋白定量与VEGF呈正相关,提示VEGF可能通过增加呼吸膜的通透性参与ALI的病理生理过程。
第二部分抑制血管内皮细胞生长因子治疗对急性肺损伤的治疗作用
目的研究抗VEGF治疗对ALI病理生理变化的影响以及抗VEGF对ALI可能存在的治疗作用。方法将60只雄性BALB/c小鼠随机分为4组,分别为PBS组、sFlt组、LPS组和LPS+sFlt组,再按时间点将每组动物分为3个亚组(4h组、24h组、48h组),所有动物麻醉后行气插管,LPS组和LPS+sFlt组吸入LPS (3mg/kg), PBS组和sFlt组吸入等容量PBS,然后sFlt组和LPS+sFlt组从尾静脉给予50μg/kg的sFlt-1 (VEGF的可溶性受体,仅有与VEGF结合能力而无信号传导作用)进行抗VEGF治疗,PBS组和LPS组给予等容量PBS。在预定的时间点左心室穿刺,行血气分析；保留血浆检测VEGF水平；BALF检测VEGF水平和蛋白定量；留取肺组织行病理学检测、免疫组化检测以及实时定量PCR检测VEGF mRNA表达水平。结果PBS组和sFlt组均无肺损伤改变,与LPS各亚组相比,LPS+sFlt各亚组的血气和病理指标均有所改善,与LPS 24h组相比,LPS+sFlt 24h组的低氧血症(64.24±10.53 mmHg vs 84.31±7.23 mmHg,P<0.001)和酸中毒(7.17±0.05 vs 7.29±0.07,P<0.05)明显减轻,且无二氧化碳潴留(49.00±9.19 mmHg vs 36.51±4.83 mmHg, P<0.05);肺损伤评分(12 vs 6,P<0.05)和BALF蛋白定量(569.17±114.68μg/ml vs 264.82±76.92μg/ml,P<0.05)均明显降低；与LPS组相比,LPS+sFlt组血浆(31.53±1.96 pg/ml vs 39.69±8.98 pg/ml, P>0.05)、BALF (160.14±34.25 pg/ml vs 127.52±17.83 pg/ml, P>0.05)和肺组织中的VEGF及VEGF mRNA (0.55±0.10 vs 0.66±0.10, P>0.05)的表达均无明显变化。结论sFlt-1能够有效地改善ALI的症状,其作用机制可能是通过竞争性抑制VEGFR-1与VEGF的结合,从而抑制VEGF的作用,维持了呼吸膜的形态和功能,改善ALI模型的血气分析和病理评分,减少血浆蛋白的渗漏。
第三部分抑制血管内皮细胞生长因子对肺损伤保护机制的研究
目的探讨VEGF在LPS吸入导致的ALI模型中的作用机制及sFlt对ALI的保护机制。方法将60只雄性BALB/c小鼠随机分为4组,分别为PBS组、sFlt组、LPS组和LPS+sFlt组,再按时间点将每组动物分为3个亚组(4h组、24h组、48h组),所有动物麻醉后插入气管导管,LPS组和LPS+sFlt组吸入LPS (3mg/kg), PBS组和sFlt组吸入等量PBS, sFlt组和LPS+sFlt组从尾静脉给予50μg/kg的sFlt-1, PBS组和LPS组给予等量PBS。在预定的时间点放血处死动物,留取肺组织进行超微病理学检测并计算凋亡指数,实时定量PCR检测凋亡蛋白Bcl2、BAX mRNA的表达水平。结果LPS各组肺泡上皮细胞紧密连接松解,肺泡上皮通透性增加,呼吸膜肿胀增厚,sFlt-1明显改善ALI肺组织中肺泡上皮细胞的紧密连接松解,减少BALF蛋白渗漏,降低呼吸膜厚度,但对肺泡上皮细胞的凋亡指数和凋亡蛋白Bcl2、BAX mRNA的表达水平没有明显影响。结论在LPS导致的ALI模型中,VEGF使肺泡上皮细胞紧密连接松解、呼吸膜通透性升高、血浆蛋白渗漏增加、呼吸膜充血、水肿、增厚,导致气体交换障碍。sFlt-1能阻断VEGF的作用,有效维护呼吸膜的正常形态和功能,改善ALI的症状。
结论
1.本实验采用气管内滴入LPS,成功建立了ALI动物模型。
2.在LPS吸入导致的ALI模型中,血浆、BALF和肺组织中的VEGF升高,BALF中VEGF与蛋白定量呈正比,提示VEGF升高参与了LPS所致ALI的病理生理过程。
3.采用sFlt-1进行抗VEGF治疗能有效改善ALI导致的低氧、二氧化碳潴留和酸中毒,降低BALF蛋白含量和肺损伤评分。
4. VEGF升高使肺泡上皮细胞紧密连接松解,呼吸膜通透性增加,导致了血浆蛋白渗漏,呼吸膜增厚和气体交换障碍。
5.sFlt-1治疗ALI的机理在于减轻了VEGF导致的肺泡上皮细胞紧密连接松解,维持呼吸膜正常的形态和功能,减少ALI导致的水和蛋白的渗出。
Part I The expression of vascular endothelial growth factor in endotoxin-induced acute lung injury model
Objective To investigate the expression of vascular endothelial growth factor in endotoxin-induced acute lung injury model. Methods Thirty male BALB/c mice were randomly assigned to one of the six groups:LPS 4h group, LPS 24h group, LPS 48h group, PBS 4h group, PBS 24h group, and PBS 48h group. All animals were anesthetized by pentobarbital sodium. LPS (3 mg/kg) was intratracheally instilled via tracheal tube through the trachea to the mice in the LPS group. Mice in the PBS group were instilled an equal volume of PBS as control. Blood gas analysis and vascular endothelial growth factor (VEGF) were measured at predefined time points. Pathohistological change, VEGF and total protein levels in bronchoalveolar lavage fluid were measured. Result Endotoxin administration resulted in an elevation of VEGF (12.44±4.05 pg/ml vs 31.53±1.96 pg/ml, P<0.05) associated with hypoxia (97.27±8.96 mmHg vs 64.24±10.53 mmHg, P< 0.001), carbon dioxide accumulation (37.83±5.75 mmHg vs 49.00±9.19 mmHg, P< 0.05), pulmonary edema, an increase of total protein (183.28±15.58μg/ml vs 569.17±114.68μg/ml, P< 0.05) and VEGF (32.45±6.57 pg/ml vs 160.14±34.25 pg/ml, P< 0.05) in bronchoalveolar lavage fluid. Total protein significantly correlated with VEGF in bronchoalveolar lavage fluid (r=0.676, P< 0.001). The extent of histological abnormalities as assessed by lung injury score peaked at 24 h after LPS challenge.
Conclusion Our research indicated that increased VEGF expression may be implicated in the pathogenesis of endotoxin-induced acute lung injury model.
Part II Protective effects of anti-vascular endothelial growth factor therapy in endotoxin-induced acute lung injury model
Objective To explore the effect of intervention with anti-vascular endothelial growth factor in endotoxin-induced acute lung injury (ALI) model. Methods Sixty mice were randomly assigned to the PBS group (n=15), LPS group (n=15), sFlt group (n=15), and LPS+sFlt group (n=15). Mice in the four groups were then subdivided into three subgroups (4 h,24 h, and 48 h groups, n=5), respectively. All animals were anesthetized by pentobarbital sodium. LPS (3 mg/kg) was intratracheally instilled via tracheal tube through the trachea to the mice in the LPS group and LPS+sFlt group. Mice in the PBS group and sFlt group were instilled an equal volume of PBS as control. Then sFlt-1(50μg/kg) was infused via tail vein to the mice in the sFlt and LPS+sFlt group. The mice in the PBS and LPS groups were given an equal volume of PBS as control. At predefined time points blood gas analysis, pathohistological change, VEGF and total protein levels in bronchoalveolar lavage fluid were measured. Result Anti-VEGF therapy with sFlt-1 attenuated the hypoxia (64.24±10.53 mmHg vs 84.31±7.23 mmHg, P<0.001), carbon dioxide accumulation (49.00±9.19 mmHg vs 36.51±4.83 mmHg, P< 0.05), and total protein (569.17±114.68μg/ml vs 264.82±76.92μg/ml, P< 0.05) in bronchoalveolar lavage fluid. sFlt-1 administration did not change the level of VEGF in plasma (31.53±1.96 pg/ml vs 39.69±8.98 pg/ml, P>0.05) and BALF (160.14±34.25 pg/ml vs 127.52±17.83 pg/ml, P>0.05). Conclusion Anti-VEGF therapy with sFlt-1 improves the blood gas analysis and attenuates pathohistological development of ALI. sFlt-1 administration might attenuate the thickness of the alveolar-capillary membrane.
Part III Protective effects and mechanisms of anti-vascular endothelial
growth factor therapy in endotoxin-induced acute lung injury model
Objective To investigate the possible mechanism of anti-VEGF therapy in endotoxin-induced acute lung injury (ALI) model. Methods Sixty mice were randomly assigned to the PBS group (n=15), LPS group (n=15), sFlt group (n=15), and LPS+sFlt group (n=15). Mice in the four groups were then subdivided into three subgroups (4 h,24 h, and 48 h groups, n=5), respectively. All animals were anesthetized by pentobarbital sodium. LPS (3 mg/kg) was intratracheally instilled via tracheal tube through the trachea to the mice in the LPS group and LPS+sFlt group. Mice in the PBS group and sFlt group were instilled an equal volume of PBS.Then sFlt-1 (50μg/kg) was infused via tail vein to the mice in the sFlt and LPS+sFlt group. The mice in the PBS and LPS groups were given an equal volume of PBS. At predefined time points, pathohistology of alveolar epithelial barrier, apoptosis index, and the anti-apoptotic protein mRNA express were studied. Result PBS and sFlt group showed intact alveolar-capillary membrane, whereas LPS challenge caused the solution of tight junction between alveolar epithelial cells, type I alveolar epithelial cell shrinkage and detachment from the basement membrane, thickness of the alveolar-capillary membrane and infiltration of cellulose into alveolar spaces. sFlt-1 administration attenuated the solution of tight junction and the thickness of the alveolar-capillary membrane in LPS+sFlt group, but sFlt-1 did not increased the alveoli epithelial cells apoptosis index. Conclusion VEGF causes an increase in the permeability of the lung by breaking lung alveolar-capillary barrier. Anti-VEGF therapy improves the blood gas analysis and attenuates pathohistological development of ALI by decreasing the permeability of alveolar epithelial barrier.
Conclusion
1. LPS-induced ALI is associated with increased mRNA expression of VEGF in lung tissue and elevated levels of VEGF in blood, lung, and BALF.
2. Increased VEGF causes an increase in the permeability of the lung by breaking lung alveolar-capillary barrier.
3. Anti-VEGF therapy improves the blood gas analysis and attenuates pathohistological development of ALI.
4. Reducing VEGF by treatment with sFlt-1 attenuates the pulmonary edema by decreasing decreasing the permeability of alveolar epithelial barrier.
目的探讨脂多糖(LPS)吸入导致急性肺损伤(ALI)模型中血管内皮细胞生长因子(VEGF)表达的变化情况及其与肺损伤程度的关系。方法将30只雄性BALB/c小鼠随机分为6组(n=5),分别为LPS 4h组、LPS 24h组、LPS 48h组、PBS 4h组、PBS 24h组和PBS 48h组,麻醉后行气管内插管,LPS组吸入LPS (3mg/kg), PBS组吸入等容量磷酸盐缓冲液(PBS)作为对照。在预定的时间点(4h,24h,48h)左心室穿刺,行血气分析；保留血浆检测VEGF水平；肺泡灌洗液(BALF)检测VEGF水平和蛋白定量；留取肺组织行病理学检测、免疫组化检测以及实时定量PCR检测VEGF mRNA表达水平。结果与PBS各组相比,LPS组均出现明显的肺损伤改变,其中LPS 24h组的病理变化最为明显,肺损伤评分显著增加(1.5 vs 12,P<0.001)；与PBS 24h组相比：LPS 24h组出现明显低氧血症(97.27±8.96 mmHg vs 64.24±10.53 mmHg, P<0.001)、二氧化碳潴留(37.83±5.75 mmHg vs 49.00±9.19 mmHg, P< 0.05)和酸中毒(7.42±0.07 vs 7.17±0.05, P< 0.001); BALF中蛋白定量(183.28±15.58μg/ml vs 569.17±114.68μg/ml, P<0.05)和VEGF(32.45±6.57 pg/ml vs 160.14±34.25 pg/ml, P<0.05)均明显增加,且二者呈正相关(r=0.676,P<0.001)；血浆(12.44±4.05 pg/ml vs 31.53±1.96 pg/ml, P<0.05)和肺组织中VEGF升高,肺组织中VEGF mRNA表达也升高(0.24±0.07 vs 0.55±0.10,P<0.05)。结论LPS吸入成功地建立了ALI模型,ALI模型的血浆、肺组织和BALF中VEGF水平明显升高,BALF中蛋白定量与VEGF呈正相关,提示VEGF可能通过增加呼吸膜的通透性参与ALI的病理生理过程。
第二部分抑制血管内皮细胞生长因子治疗对急性肺损伤的治疗作用
目的研究抗VEGF治疗对ALI病理生理变化的影响以及抗VEGF对ALI可能存在的治疗作用。方法将60只雄性BALB/c小鼠随机分为4组,分别为PBS组、sFlt组、LPS组和LPS+sFlt组,再按时间点将每组动物分为3个亚组(4h组、24h组、48h组),所有动物麻醉后行气插管,LPS组和LPS+sFlt组吸入LPS (3mg/kg), PBS组和sFlt组吸入等容量PBS,然后sFlt组和LPS+sFlt组从尾静脉给予50μg/kg的sFlt-1 (VEGF的可溶性受体,仅有与VEGF结合能力而无信号传导作用)进行抗VEGF治疗,PBS组和LPS组给予等容量PBS。在预定的时间点左心室穿刺,行血气分析；保留血浆检测VEGF水平；BALF检测VEGF水平和蛋白定量；留取肺组织行病理学检测、免疫组化检测以及实时定量PCR检测VEGF mRNA表达水平。结果PBS组和sFlt组均无肺损伤改变,与LPS各亚组相比,LPS+sFlt各亚组的血气和病理指标均有所改善,与LPS 24h组相比,LPS+sFlt 24h组的低氧血症(64.24±10.53 mmHg vs 84.31±7.23 mmHg,P<0.001)和酸中毒(7.17±0.05 vs 7.29±0.07,P<0.05)明显减轻,且无二氧化碳潴留(49.00±9.19 mmHg vs 36.51±4.83 mmHg, P<0.05);肺损伤评分(12 vs 6,P<0.05)和BALF蛋白定量(569.17±114.68μg/ml vs 264.82±76.92μg/ml,P<0.05)均明显降低；与LPS组相比,LPS+sFlt组血浆(31.53±1.96 pg/ml vs 39.69±8.98 pg/ml, P>0.05)、BALF (160.14±34.25 pg/ml vs 127.52±17.83 pg/ml, P>0.05)和肺组织中的VEGF及VEGF mRNA (0.55±0.10 vs 0.66±0.10, P>0.05)的表达均无明显变化。结论sFlt-1能够有效地改善ALI的症状,其作用机制可能是通过竞争性抑制VEGFR-1与VEGF的结合,从而抑制VEGF的作用,维持了呼吸膜的形态和功能,改善ALI模型的血气分析和病理评分,减少血浆蛋白的渗漏。
第三部分抑制血管内皮细胞生长因子对肺损伤保护机制的研究
目的探讨VEGF在LPS吸入导致的ALI模型中的作用机制及sFlt对ALI的保护机制。方法将60只雄性BALB/c小鼠随机分为4组,分别为PBS组、sFlt组、LPS组和LPS+sFlt组,再按时间点将每组动物分为3个亚组(4h组、24h组、48h组),所有动物麻醉后插入气管导管,LPS组和LPS+sFlt组吸入LPS (3mg/kg), PBS组和sFlt组吸入等量PBS, sFlt组和LPS+sFlt组从尾静脉给予50μg/kg的sFlt-1, PBS组和LPS组给予等量PBS。在预定的时间点放血处死动物,留取肺组织进行超微病理学检测并计算凋亡指数,实时定量PCR检测凋亡蛋白Bcl2、BAX mRNA的表达水平。结果LPS各组肺泡上皮细胞紧密连接松解,肺泡上皮通透性增加,呼吸膜肿胀增厚,sFlt-1明显改善ALI肺组织中肺泡上皮细胞的紧密连接松解,减少BALF蛋白渗漏,降低呼吸膜厚度,但对肺泡上皮细胞的凋亡指数和凋亡蛋白Bcl2、BAX mRNA的表达水平没有明显影响。结论在LPS导致的ALI模型中,VEGF使肺泡上皮细胞紧密连接松解、呼吸膜通透性升高、血浆蛋白渗漏增加、呼吸膜充血、水肿、增厚,导致气体交换障碍。sFlt-1能阻断VEGF的作用,有效维护呼吸膜的正常形态和功能,改善ALI的症状。
结论
1.本实验采用气管内滴入LPS,成功建立了ALI动物模型。
2.在LPS吸入导致的ALI模型中,血浆、BALF和肺组织中的VEGF升高,BALF中VEGF与蛋白定量呈正比,提示VEGF升高参与了LPS所致ALI的病理生理过程。
3.采用sFlt-1进行抗VEGF治疗能有效改善ALI导致的低氧、二氧化碳潴留和酸中毒,降低BALF蛋白含量和肺损伤评分。
4. VEGF升高使肺泡上皮细胞紧密连接松解,呼吸膜通透性增加,导致了血浆蛋白渗漏,呼吸膜增厚和气体交换障碍。
5.sFlt-1治疗ALI的机理在于减轻了VEGF导致的肺泡上皮细胞紧密连接松解,维持呼吸膜正常的形态和功能,减少ALI导致的水和蛋白的渗出。
Part I The expression of vascular endothelial growth factor in endotoxin-induced acute lung injury model
Objective To investigate the expression of vascular endothelial growth factor in endotoxin-induced acute lung injury model. Methods Thirty male BALB/c mice were randomly assigned to one of the six groups:LPS 4h group, LPS 24h group, LPS 48h group, PBS 4h group, PBS 24h group, and PBS 48h group. All animals were anesthetized by pentobarbital sodium. LPS (3 mg/kg) was intratracheally instilled via tracheal tube through the trachea to the mice in the LPS group. Mice in the PBS group were instilled an equal volume of PBS as control. Blood gas analysis and vascular endothelial growth factor (VEGF) were measured at predefined time points. Pathohistological change, VEGF and total protein levels in bronchoalveolar lavage fluid were measured. Result Endotoxin administration resulted in an elevation of VEGF (12.44±4.05 pg/ml vs 31.53±1.96 pg/ml, P<0.05) associated with hypoxia (97.27±8.96 mmHg vs 64.24±10.53 mmHg, P< 0.001), carbon dioxide accumulation (37.83±5.75 mmHg vs 49.00±9.19 mmHg, P< 0.05), pulmonary edema, an increase of total protein (183.28±15.58μg/ml vs 569.17±114.68μg/ml, P< 0.05) and VEGF (32.45±6.57 pg/ml vs 160.14±34.25 pg/ml, P< 0.05) in bronchoalveolar lavage fluid. Total protein significantly correlated with VEGF in bronchoalveolar lavage fluid (r=0.676, P< 0.001). The extent of histological abnormalities as assessed by lung injury score peaked at 24 h after LPS challenge.
Conclusion Our research indicated that increased VEGF expression may be implicated in the pathogenesis of endotoxin-induced acute lung injury model.
Part II Protective effects of anti-vascular endothelial growth factor therapy in endotoxin-induced acute lung injury model
Objective To explore the effect of intervention with anti-vascular endothelial growth factor in endotoxin-induced acute lung injury (ALI) model. Methods Sixty mice were randomly assigned to the PBS group (n=15), LPS group (n=15), sFlt group (n=15), and LPS+sFlt group (n=15). Mice in the four groups were then subdivided into three subgroups (4 h,24 h, and 48 h groups, n=5), respectively. All animals were anesthetized by pentobarbital sodium. LPS (3 mg/kg) was intratracheally instilled via tracheal tube through the trachea to the mice in the LPS group and LPS+sFlt group. Mice in the PBS group and sFlt group were instilled an equal volume of PBS as control. Then sFlt-1(50μg/kg) was infused via tail vein to the mice in the sFlt and LPS+sFlt group. The mice in the PBS and LPS groups were given an equal volume of PBS as control. At predefined time points blood gas analysis, pathohistological change, VEGF and total protein levels in bronchoalveolar lavage fluid were measured. Result Anti-VEGF therapy with sFlt-1 attenuated the hypoxia (64.24±10.53 mmHg vs 84.31±7.23 mmHg, P<0.001), carbon dioxide accumulation (49.00±9.19 mmHg vs 36.51±4.83 mmHg, P< 0.05), and total protein (569.17±114.68μg/ml vs 264.82±76.92μg/ml, P< 0.05) in bronchoalveolar lavage fluid. sFlt-1 administration did not change the level of VEGF in plasma (31.53±1.96 pg/ml vs 39.69±8.98 pg/ml, P>0.05) and BALF (160.14±34.25 pg/ml vs 127.52±17.83 pg/ml, P>0.05). Conclusion Anti-VEGF therapy with sFlt-1 improves the blood gas analysis and attenuates pathohistological development of ALI. sFlt-1 administration might attenuate the thickness of the alveolar-capillary membrane.
Part III Protective effects and mechanisms of anti-vascular endothelial
growth factor therapy in endotoxin-induced acute lung injury model
Objective To investigate the possible mechanism of anti-VEGF therapy in endotoxin-induced acute lung injury (ALI) model. Methods Sixty mice were randomly assigned to the PBS group (n=15), LPS group (n=15), sFlt group (n=15), and LPS+sFlt group (n=15). Mice in the four groups were then subdivided into three subgroups (4 h,24 h, and 48 h groups, n=5), respectively. All animals were anesthetized by pentobarbital sodium. LPS (3 mg/kg) was intratracheally instilled via tracheal tube through the trachea to the mice in the LPS group and LPS+sFlt group. Mice in the PBS group and sFlt group were instilled an equal volume of PBS.Then sFlt-1 (50μg/kg) was infused via tail vein to the mice in the sFlt and LPS+sFlt group. The mice in the PBS and LPS groups were given an equal volume of PBS. At predefined time points, pathohistology of alveolar epithelial barrier, apoptosis index, and the anti-apoptotic protein mRNA express were studied. Result PBS and sFlt group showed intact alveolar-capillary membrane, whereas LPS challenge caused the solution of tight junction between alveolar epithelial cells, type I alveolar epithelial cell shrinkage and detachment from the basement membrane, thickness of the alveolar-capillary membrane and infiltration of cellulose into alveolar spaces. sFlt-1 administration attenuated the solution of tight junction and the thickness of the alveolar-capillary membrane in LPS+sFlt group, but sFlt-1 did not increased the alveoli epithelial cells apoptosis index. Conclusion VEGF causes an increase in the permeability of the lung by breaking lung alveolar-capillary barrier. Anti-VEGF therapy improves the blood gas analysis and attenuates pathohistological development of ALI by decreasing the permeability of alveolar epithelial barrier.
Conclusion
1. LPS-induced ALI is associated with increased mRNA expression of VEGF in lung tissue and elevated levels of VEGF in blood, lung, and BALF.
2. Increased VEGF causes an increase in the permeability of the lung by breaking lung alveolar-capillary barrier.
3. Anti-VEGF therapy improves the blood gas analysis and attenuates pathohistological development of ALI.
4. Reducing VEGF by treatment with sFlt-1 attenuates the pulmonary edema by decreasing decreasing the permeability of alveolar epithelial barrier.
引文
1. Bernard GR, Artigas A, Brigham KL, et al. Report of the American-European Consensus Conference on acute respiratory distress syndrome:definitions, mechanisms, relevant outcomes, and clinical trial coordination. J Crit Care,1994,9:72-81.
2. Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med,2004,351: 884-892.
3. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med,2005,353:1685-1693.
4. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science,1989,246:1306-1309.
5. Ferrara N. VEGF:an update on biological and therapeutic aspects. Curr Opin Biotechnol,2000,11(6):617-624.
6. Zebrowski BK, Yano S, Liu W, et al.Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res,1999,5(11): 3364-3368.
7. Schoch HJ, Fischer S, Marti HH. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain,2002,125:2549-2557.
8. Kaner RJ, Ladetto JV, Singh R, et al. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol,2000,22: 657-664.
9. Otani N, Minami S, Yamoto M, et al. The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy. J Clin Endocrinol Metab,1999,84(10):3845-3851.
10. Fraser HM. Regulation of the ovarian follicular vasculature. Reprod Biol Endocrinol, 2006,4(1):18.
11. Koyama S, Sato E, Tsukadaira A, et al. Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro. Eur Respir J,2002,20: 1449-1456.
12. Saint-Geniez M, Maldonado AE, D'Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci,2006,47(7):3135-3142.
13. Ng YS, Rohan R, Sunday ME, et al. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn,2001,220(2):112-121.
14. Bernini GP, Moretti A, Bonadio AG, et al. Angiogenesis in human normal and pathologic adrenal cortex. J Clin Endocrinol Metab,2002,87(11):4961-4965.
15. Maharaj AS, Saint-Geniez M, Maldonado AE, et al. Vascular endothelial growth factor localization in the adult. Am J Pathol,2006,168(2):639-648.
16. Taichman NS, Cruchley AT, Fletcher LM, et al. Vascular endothelial growth factor in normal human salivary glands and saliva:a possible role in the maintenance of mucosal homeostasis. Lab Invest,1998,78(7):869-875.
17. Katoh R. Angiogenesis in endocrine glands:special reference to the expression of vascular endothelial growth factor. Microsc Res Tech,2003,60(2):181-185.
18. Acker T, Beck H, Plate KH. Cell type specific expression of vascular endothelial growth factor and angiopoietin-1 and -2 suggests an important role of astrocytes in cerebellar vascularization. Mech Dev,2001,108(1-2):45-57.
19. Storkebaum E, Lambrechts D, Carmeliet P. VEGF:once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays,2004,26(9):943-954.
20. Del BR, Scarlato M, Ghezzi S, et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol,2005,57(3):373-380.
21. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet,2003,34(4):383-394.
22. Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci,2005,8(1):85-92.
23. Devos D, Moreau C, Lassalle P, et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology,2004,62(11):2127-2129.
24. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet,2001,28(2):131-138.
25. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res,1997,57:4593-4599.
26. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina,2006,26(5):495-511.
27. Berse B, Brown LF, Van-de WL, et al. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumours. Mol Biol Cell,1992,3:211-220.
28. Koyama S, Sato E, Tsukadaira A, et al. Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro. Eur Respir J,2002,20: 1449-1456.
29. Boussat S, Eddahibi S, Coste A, et al. Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol,2000,279:L371-378.
30. Kaner RJ, Crystal RG. Compartmentalization of vascular endothelial growth factor to the epithelial surface of the human lung. Mol Med,2001,7:240-246.
31. Fehrenbach A, Pufe T, Wittwer T, et al. Reduced vascular endothelial growth factor correlates with alveolar epithelial damage after experimental ischemia and reperfusion. J Heart Lung Transplant,2003,22:967-978.
32. Asai K, Kanazawa H, Kamoi H, et al. Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin Exp Allergy,2003,33(5):595-599.
33. Chetta A, Zanini A, Foresi A, et al. Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma. Clin Exp Allergy,2005,35(11):1437-1442.
34. Hoshino M, Nakamura Y, Hamid QA. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol, 2001,107(6):1034-1038.
35. Kanazawa H, Hirata K, Yoshikawa J. Involvement of vascular endothelial growth factor in exercise induced bronchoconstriction in asthmatic patients. Thorax,2002,57(10): 885-888.
36. Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways andits relationship to angiogenesis. J Allergy Clin Immunol,2001,107(2):295-301.
37. Feltis BN, Wignarajah D, Zheng L, et al. Increased vascular endothelial growth factor and receptors:relationship to angiogenesis in asthma. Am J Respir Crit Care Med,2006, 173(11):1201-1207.
38. Asai K, Kanazawa H, Otani K, et al. Imbalance between vascular endothelial growth factor and endostatin levels in induced sputum from asthmatic subjects. J Allergy Clin Immunol,2002,110(4):571-575.
39. Kishiro I, Kato S, Fuse D, et al. Clinical significance of vascular endothelial growth factor in patients with primary lung cancer. Respirology,2002,7(2):93-98.
40. Cressey R, Wattananupong O, Lertprasertsuke N, et al. Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis. BMC Cancer,2005,5:128-136.
41. Kiropoulos TS, Kostikas K, Gourgoulianis KI. Vascular endothelial growth factor levels in pleural fluid and serum of patients with tuberculous pleural effusions. Chest,2005, 128(1):468-469.
42. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer,1999,85(1): 178-187.
1. Bernard GR, Artigas A, Brigham KL, et al. Report of the American-European Consensus Conference on acute respiratory distress syndrome:definitions, mechanisms, relevant outcomes, and clinical trial coordination. J Crit Care,1994,9: 72-81.
2. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med,2005,353:1685-1693.
3. Faridy EE, Permutt S, Riley RL. Effect of ventilation on surface forces in excised dogs'lungs. J Appl Physiol,1966,21:1453-1462.
4. Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med,2004, 351:884-892.
5. Ferrara N. VEGF:an update on biological and therapeutic aspects. Curr Opin Biotechnol,2000,11(6):617-624.
6. Zebrowski BK, Yano S, Liu W, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res,1999,5(11): 3364-3368.
7. Masood R, Cai J, Zheng T, et al. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci USA,1997,94(3):979-984.
8. Balamurali KA, Miho N, Nirbhai S, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature,2006,443:993-997.
9. Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol,2006,290(2):L209-221.
10. Medford AR, Millar AB. Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS):paradox or paradigm? Thorax,2006,61(7):621-626.
11. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med, 2003,9:669-676.
12. Poltorak Z, Cohen T, Neufeld G. The VEGF splice variants:properties, receptors, and usage for the treatment of ischemic diseases. Herz,2000,25:126-129.
13. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci,2001,114:853-865.
14. Nagase T, Uozumi N, Ishii S, et al. Acute lung injury by sepsis and acid aspiration:a key role for cytosolic phospholipase A2. Nat Immunol,2000,1(1):42-46.
15. Zheng CH, Gao JQ, Zhang YP, et al. A protein delivery system:biodegradable alginate-chitosan-poly (lactic-co-glycolic acid) composite microspheres. Biochem Biophys Res Commun,2004,323(4):1321-1327.
16. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science,1989,246 (4935):1309-1312.
17. Yang SP, Bae DG, Kang HJ, et al. Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging,2004,25(3):283-290.
18. Michael WP. A new mathematical model for relative quantification in real- time RT-PCR. Nucleic Acids Res,2001,29 (9):2002-2007.
19. Ashbaugh DG, Bigelow DB, Petty TL, et al. Acute respiratory distress syndrome. Lancet,1967,2:319-323.
20. Po-Nien T, Feng-Tsan C, Shu-Chen W, et al. Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis. Crit Care Med,2007,35:1955-1960.
21. Rocco PR, Zin WA. Pulmonary and extrapulmonary acute respiratory distress syndrome:are they different? Curr Opin Crit Care,2005,11(1):10-17.
22. Pelosi PD, Onofrio D, Chiumello D. Pulmonary and extrapulmonary acute respiratory distress syndrome are different. Eur Respir J,2003,22:48-56.
23. Hoelz C, Negri EM, Lichtenfels AJ, et al. Morphometric differences in pulmonary
lesions in primary and secondary ARDS:a preliminary study in autopsies. Pathol Res Pract,2001,197:521-530.
24. Berse B, Brown LF, Van-de WL, et al. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumours. Mol Biol Cell,1992,3:211-220.
25. Koyama S, Sato E, Tsukadaira A, et al. Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro. Eur Respir J,2002,20: 1449-1456.
26. Boussat S, Eddahibi S, Coste A, et al. Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol,2000,279:L371-378.
27. Kaner RJ, Crystal RG. Compartmentalization of vascular endothelial growth factor to the epithelial surface of the human lung. Mol Med,2001,7:240-246.
28. Marco M, Claudia CS, Duncan S, et al. Vascular endothelial growth factor and related molecules in acute lung injury. J Appl Physiol,2004,97:1605-1617.
1. Tsao PN, Chan FT, Wei SC, et al. Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis. Crit Care Med,2007,35:1955-1960.
2. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA,1993,90: 10705-10709.
3. Nagase T, Uozumi N, Ishii S, et al. Acute lung injury by sepsis and acid aspiration:a key role for cytosolic phospholipase A2. Nat Immunol,2000,1(1):42-46.
4. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science,1989,246 (4935):1309-1312.
5. Zheng CH, Gao JQ, Zhang YP, et al. A protein delivery system:biodegradable alginate-chitosan-poly (lactic-co-glycolic acid) composite microspheres. Biochem Biophys Res Commun,2004,323(4):1321-1327.
6. Yang SP, Bae DG, Kang HJ, et al. Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging,2004,25(3):283-290.
7. Michael WP. A new mathematical model for relative quantification in real- time RT-PCR. Nucleic Acids Res,2001,29 (9):2002-2007.
8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med, 2003,9:669-676.
9. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J Biol Chem,1994,269:26988-26995.
10. Seetharam L, Gotoh N, Maru Y, et al. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene,1995,10: 135-147.
11. Terman BI, Dougher VM, Carrion ME, et al. Identification of the KDR tyrosine kinase
as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun,1992,187:1579-1586.
12. Barleon B, Hauser S, Schollmann C, et al. Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells. J Cell Biochem,1994, 54:56-66.
13. Charnock-Jones DS, Sharkey AM, Boocock CA, et al. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. Biol Reprod,1994,51:524-530.
14. Fehrenbach H, Haase M, Kasper M, et al. Alterations in the immunohistochemical distribution patterns of vascular endothelial growth factor receptors Flkl and Fltl in bleomycin-induced rat lung fibrosis. Virchows Arch,1999,435:20-31.
15. Brown KR, England KM, Goss KL, et al. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol,2001, 281:L1001-1010.
16. Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature,1995,376:66-70.
17. Fong GH, Zhang L, Bryce DM, et al. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development, 1999,126:3015-3025.
18. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood,1996,87:3336-3343.
19. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J,1996,15:290-298.
20. Lee J, Gray A, Yuan J, et al. Vascular endothelial growth factor-related protein:a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA,1996,93:1988-1992.
21. Balamurali KA, Miho N, Nirbhai S, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature,2006,443:993-997.
22. Volker Schmitz, Miroslaw Kornek, Tobias Hilbert. Treatment of metastatic colorectal carcinomas by systemic inhibition of vascular endothelial growth factor signaling in mice. World J Gastroenterol,2005,11(28):4332-4336.
23. Kiichiro Y, Patricia CL, Janet MM. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. The Journal of Experimental Medicine, 2006,203:1447-1458.
1. Kaner RJ, Ladetto JV, Singh R, et al. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary oedema. Am J Respir Cell Mol Biol,2000,22: 657-664.
2. Bardales RH, Hailey LS, Xie SS, et al. In situ apoptosis assay for the detection of early acute myocardial infarction. Am J Pathol,1996,149:821-829.
3. Wijsman JH, Jonker RR, Keijzer R, et al. A new method to detect apoptosis in paraffin sections:in situ end-labeling of fragmented DNA. The Journal of Histochemistry and Cytochemistry,1993,41:7-12.
4. Schneeberger EE, Lynch RD. Structure, function, and regulation of cellular tight junctions. Am J Physiol,1992,262(6):L647-661.
5. Michael WP. A new mathematical model for relative quantification in real- time RT-PCR. Nucleic Acids Res,2001,29 (9):2002-2007.
6. Alavi A, Hood JD, Frausto R, et al. Role of raf in vascular protection from distinct apoptotic stimuli. Science,2003,301:94-96.
7. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science,1989,246:1306-1309.
8. Ferrara N. VEGF:an update on biological and therapeutic aspects. Curr Opin Biotechnol,2000,11(6):617-624.
9. Zebrowski BK, Yano S, Liu W, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res,1999,5(11): 3364-3368.
10. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem, 1998,273:13313-13316.
11. Berthiaume Y, Hans GF, Michael AM. Lung Edema Clearance:20 years of progress invited review:alveolar edema fluid clearance in the injured lung. J Appl Physiol,2002,
93:2207-2213.
12. Bern RA, Bos AP, Matute-Bello G, et al. Lung epithelial cell apoptosis during acute lung injury in infancy. Pediatr Crit Care Med,2007,8:132-137.
13. Hans-Peter G, Vishva D, Napoleone F. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl2 and Al in vascular endothelial cells. J Biol Chem,1998,273:13313-13316.
14. Mishra DP, Dhali A. Endotoxin induces luteal cell apoptosis through the mitochondrial pathway. Epub,2007,83(1-2):75-88.
15. Kiichiro Y, Patricia CL, Janet MM, et al. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med,2006,203: 1447-1458.
16. Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF-2 alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med,2002,8:702-710.
17. Brown KR, England KM, Goss KL, et al. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol,2001, 281:L1001-1010.
18. Fehrenbach H, Haase M, Kasper M, et al. Alterations in the immunohistochemical distribution patterns of vascular endothelial growth factor receptors Flkl and Fltl in bleomycin-induced rat lung fibrosis. Virchows Arch,1999,435:20-31.
1. Ferrara N. VEGF:an update on biological and therapeutic aspects. Curr Opin Biotechnol,2000,11(6):617-624.
2. Zebrowski BK, Yano S, Liu W, et al.Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res,1999, 5(11):3364-3368.
3. Miquerol L, Gertsenstein M, Harpal K, et al. Multiple developmental roles of VEGF suggested by a LacZ-tagged allele. Dev Biol,1999,212(2):307-322.
4. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun, 1989,161(2):851-858.
5. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature,1996,380(6573):439-442.
6. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature,1996,380(6573):435-439.
7. Miquerol L, Langille BL, Nagy A. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development, 2000,127 (18):3941-3946.
8. Bates DO, Hillman NJ, Williams B, et al. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat,2002,200:581-597.
9. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1995,1(1):27-31.
10. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature,2000, 407(6801):249-257.
11. Moreno PR, Purushothaman KR, Sirol M, et al. Neovascularization in human atherosclerosis. Circulation,2006,113 (18):2245-2252.
12. Yano K, Liaw PC, Mullington JM, et al. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med,2006,203 (6): 1447-1458.
13. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science,1989,246:1306-1309.
14. Napoleone F, Hans-Peter G, Jennifer L. The biology of VEGF and its receptors. Nature,2003,9:669-676.
15. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and Al in vascular endothelial cells. J Biol Chem, 1998,273:13313-13316.
16. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med, 2003,9:669-676.
17. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science,1983,219(4587): 983-985.
18. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res,2001,49(3): 568-581.
19. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J Biol Chem,1994,269:26988-26995.
20. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med, 2003,9:669-676.
21. Poltorak Z, Cohen T, Neufeld G. The VEGF splice variants:properties, receptors, and usage for the treatment of ischemic diseases. Herz,2000,25:126-129.
22. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci,2001,114:853-865.
23. Olofsson B, Pajusola K, Kaipainen A, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA,1996,93: 2576-2581.
24. Wanstall JC, Gambino A, Jeffery TK, et al. Vascular endothelial growth factor-B deficient mice show impaired development of hypoxic pulmonary hypertension. Cardiovasc Res,2002,55:361-368.
25. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science,1997,276:1423-1425.
26. Cao R, Eriksson A, Kubo H, et al. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res,2004,94:664-670.
27. Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med,2002, 196:1497-1506.
28. Paavonen K, Mandelin J, Partanen T, et al. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium. J Rheumatol,2002,29:39-45.
29. Skobe M, Hamberg LM, Hawighorst T, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol,2001,159:893-903.
30. Autiero M, Waltenberger J, Communi D, et al. Role of P1GF in the intra- and intermolecular cross talk between the VEGF receptors Fltl and Flkl. Nat Med,2003, 9:936-943.
31. Cao Y, Chen H, Zhou L, et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem,1996,271:3154-3162.
32. Hauser S, Weich HA. A heparin-binding form of placenta growth factor (P1GF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors, 1993,9:259-268.
33. Persico MG, Vincenti V, Dipalma T. Structure, expression and receptor-binding properties of placenta growth factor (P1GF). Curr Top Microbiol Immunol,1999,237: 31-40.
34. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med,2001,7:575-583.
35. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med, 2003,9:669-676.
36. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J Biol Chem,1994,269:26988-26995.
37. Seetharam L, Gotoh N, Maru Y, et al. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene,1995,10: 135-147.
38. Terman BI, Dougher VM, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun,1992,187:1579-1586.
39. Barleon B, Hauser S, Schollmann C, et al. Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells. J Cell Biochem, 1994,54:56-66.
40. Charnock-Jones DS, Sharkey AM, Boocock CA, et al. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. Biol Reprod,1994,51:524-530.
41. Fehrenbach H, Haase M, Kasper M, et al. Alterations in the immunohistochemical distribution patterns of vascular endothelial growth factor receptors Flkl and Fltl in bleomycin-induced rat lung fibrosis. Virchows Arch,1999,435:20-31.
42. Brown KR, England KM, Goss KL, et al. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol,2001, 281:L1001-1010.
43. Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature,1995,376:66-70.
44. Fong GH, Zhang L, Bryce DM, et al. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development, 1999,126:3015-3025.
45. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood,1996,87:3336-3343.
46. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J,1996,15:290-298.
47. Lee J, Gray A, Yuan J, et al. Vascular endothelial growth factor-related protein:a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA,1996,93:1988-1992.
48. Baldwin ME, Catimel B, Nice EC, et al. The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man. J Biol Chem, 2001,276:19166-19171.
49. Lymboussaki A, Partanen TA, Olofsson B, et al. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol,1998,153:395-403.
50. Meyer M, Clauss M, Lepple-Wienhues A, et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signaling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J,1999, 18:363-374.
51. Ogawa S, Oku A, Sawano A, et al. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem,1998,273: 31273-31282.
52. Park JE, Chen HH, Winer J, et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem,1994,269:25646-25654.
53. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev, 2002,82:673-700.
54. Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA,1998,95:11709-11714.
55. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J,1996,15:290-298.
56. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J Biol Chem,1994,269:26988-26995.
57. Stevens A, Soden J, Brenchley PE, et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res,2003,63: 812-816.
58. Otani N, Minami S, Yamoto M et al. The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy. J Clin Endocrinol Metab,1999,84(10):3845-3851.
59. Fraser HM. Regulation of the ovarian follicular vasculature. Reprod Biol Endocrinol, 2006,4(1):18.
60. Berse B, Brown LF, Van-de WL, et al. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumours. Mol Biol Cell,1992,3:211-220.
61. Koyama S, Sato E, Tsukadaira A, et al. Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro. Eur Respir J,2002,20: 1449-1456.
62. Boussat S, Eddahibi S, Coste A, et al. Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol,2000,279:L371-378.
63. Saint-Geniez M, Maldonado AE, D'Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci,2006,47(7):3135-3142.
64. Ng YS, Rohan R, Sunday ME, et al. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn,2001,220(2):112-121.
65. Pammer J, Weninger W, Mildner M, et al. Vascular endothelial growth factor is constitutively expressed in normal human salivary glands and is secreted in the saliva of healthy individuals. J Pathol,1998,186 (2):186-191.
66. Bernini GP, Moretti A, Bonadio AG, et al. Angiogenesis in human normal and pathologic adrenal cortex. J Clin Endocrinol Metab,2002,87(11):4961-4965.
67. Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci USA,1998, 95(26):15809-15814.
68. Maharaj AS, Saint-Geniez M, Maldonado AE, et al. Vascular endothelial growth factor localization in the adult. Am J Pathol,2006,168(2):639-648.
69. Taichman NS, Cruchley AT, Fletcher LM, et al. Vascular endothelial growth factor in normal human salivary glands and saliva:a possible role in the maintenance of mucosal homeostasis. Lab Invest,1998,78(7):869-875.
70. Katoh R. Angiogenesis in endocrine glands:special reference to the expression of vascular endothelial growth factor. Microsc Res Tech,2003,60(2):181-185.
71. Monacci WT, Merrill MJ, Oldfield EH. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol,1993, 264:995-1002.
72. Acker T, Beck H, Plate KH. Cell type specific expression of vascular endothelial growth factor and angiopoietin-1 and -2 suggests an important role of astrocytes in cerebellar vascularization. Mech Dev,2001,108(1-2):45-57.
73. Witmer AN, Dai J, Weich HA, et al. Expression of vascular endothelial growth factor receptors 1,2, and 3 in quiescent endothelia. J Histochem Cytochem,2002,50(6): 767-777.
74. Yang SZ, Zhang LM, Huang YL, et al. Distribution of Flk-1 and Flt-1 receptors in neonatal and adult rat brains. Anat Rec A Discov Mol Cell Evol Biol,2003,274(1): 851-856.
75. Lee JW, Bae SH, Jeong JW, et al. Hypoxiainducible factor (HEF-1) alpha:its protein stability and biological functions. Exp Mol Med,2004,36:1-12.
76. Semenza GL, Agani F, Feldser D, et al. Hypoxia, HIF-1, and the pathophysiology of common human diseases. Adv Exp Med Biol,2000,475:123-130.
77. Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci USA,1998, 95:15809-15814.
78. Liu Y, Cox SR, Morita T, et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5 enhancer. Circ Res,1995, 77:638-643.
79. Chua CC, Hamdy RC, Chua BH. Upregulation of vascular endothelial growth factor by H2O2 in rat heart endothelial cells. Free Radic Biol Med,1998,25:891-897.
80. Shweiki D, Neeman M, Itin A, et al. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids:implications for tumor angiogenesis. Proc Natl Acad Sci USA,1995,92:768-772.
81. Howdieshell TR, Webb WL, Sathyanarayana, et al. Inhibition of inducible nitric oxide synthase results in reductions in wound vascular endothelial growth factor expression, granulation tissue formation, and local perfusion. Surgery,2003,133: 528-537.
82. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest,1995,95:1798-1807.
83. Boussat S, Eddahibi S, Coste A, et al. Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol,2000,279:L371-378.
84. Cohen T, Nahari D, Cerem LW, et al. Interleukin-6 induces the expression of vascular endothelial growth factor. J Biol Chem,1996,271:736-741.
85. Frank S, Hubner G, Breier G, et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem,1995,270:12607-12613.
86. Yan SF, Tritto I, Pinsky D, et al. Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6. J Biol Chem, 1995,270:11463-11471.
87. Koyama S, Sato E, Tsukadaira A, et al. Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro. Eur Respir J,2002,20: 1449-1456.
88. Trompezinski S, Denis A, Vinche A, et al. IL-4 and interferon-gamma differentially modulate vascular endothelial growth factor release from normal human keratinocytes and fibroblasts. Exp Dermatol,2002,11:224-231.
89. Wen FQ, Liu X, Manda W, et al. TH2 cytokine-enhanced and TGF-beta-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids. J Allergy Clin Immunol,2003,111:1307-1318.
90. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood,1996,87:3336-3343.
91. Becker PM, Verin AD, Booth MA, et al. Differential regulation of diverse physiological responses to VEGF in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol,2001,281:L1500-1511.
92. Becker PM, Alcasabas A, Yu AY, et al. Oxygen-independent upregulation of vascular endothelial growth factor and vascular barrier dysfunction during ventilated pulmonary ischemia in isolated ferret lungs. Am J Respir Cell Mol Biol,2000,22: 272-279.
93. Harada SI, Nagy JA, Sullivan KA, et al. Induction of vascular endothelial growth factor expression by prostaglandin E2 and El in osteoblasts. Clin Invest,1994,93: 2490-2496.
94. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature,1996,380:439-442.
95. Breier G, Damert A, Plate KH, et al. Angiogenesis in embryos and ischemic diseases. Thromb Haemost,1997,78:678-683.
96. Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci USA,1998, 95:15809-15814.
97. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature,1995,376:62-66.
98. Alavi A, Hood JD, Frausto R, et al. Role of raf in vascular protection from distinct apoptotic stimuli. Science,2003,301:94-96.
99. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway, requirement for Flk-1/KDR activation. J Biol Chem, 1998,273:30336-30343.
100. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem, 1998,273:13313-13316.
101. Tsao PN, Su YN, Li H, et al. Overexpression of placenta growth factor contributes to the pathogenesis of pulmonary emphysema. Am J Respir Crit Care Med,2004,169: 505-511.
102. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science,1989,246:1306-1309.
103. Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF-2 alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med,2002,8:702-710.
104. Brown KR, England KM, Goss KL, et al. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol,2001, 281:L1001-1010.
105. Duyndam MC, Hilhorst MC, Schluper HM, et al. Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol,2002,160 (2):537-548.
106. Clauss M, Weich H, Breier G, et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem,1996,271 (30): 17629-17634.
107. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood,1996,87(8):3336-3343.
108. Norrby K. Mast cells and angiogenesis. Apmis,2002,110(5):355-371.
109. Dikov MM, Ohm JE, Ray N, et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol,2005,174(1): 215-222.
110. Feistritzer C, Kaneider NC, Sturn DH et al. Expression and function of the vascular endothelial growth factor receptor FLT-1 in human eosinophils. Am J Respir Cell Mol Biol,2004,30(5):729-735.
111. Shui YB, Wang X, Hu JS, et al. Vascular endothelial growth factor expression and signaling in the lens. Invest Ophthalmol Vis Sci,2003,44 (9):3911-3919.
112. Casella I, Feccia T, Chelucci C, et al. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Fltl receptor. Blood,2003,101(4): 1316-1323.
113. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell,2006,124(1):175-189.
114. Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature,2002,417(6892):954-958.
115. Murayama T, Tepper OM, Silver M, et al. Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo. Exp Hematol,2002,30(8):967-972.
116. Iwaguro H, Yamaguchi J, Kalka C, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation,2002, 105(6):732-738.
117. Farahani M, Treweeke AT, Toh CH, et al. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia,2005,19(4):524-530.
118. Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med,2002,8(7):702-710.
119. Esser S, Wolburg K, Wolburg H, et al. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol,1998,140(4):947-959.
120. Eming SA, Krieg T. Molecular mechanisms of VEGF-A action during tissue repair. J Invest Dermatol,2006,126:79-86.
121. Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling- in control of vascular function. Nat Rev Mol Cell Biol,2006,7(5):359-371.
122. Maharaj AS, Saint-Geniez M, Maldonado AE, et al. Vascular endothelial growth factor localization in the adult. Am J Pathol,2006,168(2):639-648.
123. Bates DO, Hillman NJ, Williams B, et al. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat,2002,200(6):581-597.
124. Schoch HJ, Fischer S, Marti HH. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain,2002,125:2549-2557.
125. Kaner RJ, Ladetto JV, Singh R, et al. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol,2000,22: 657-664.
126. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood,1996,87:3336-3343.
127. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev, 2002,82:673-700.
128. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet,2005,365(9461): 785-799.
129. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med,2004,350(7):672-683.
130. McKeeman GC, Ardill JE, Caldwell CM, et al. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol,2004,191(4):1240-1246.
131. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFltl) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest,2003,111(5):649-658.
132. Schwartz RB, Feske SK, Polak JF, et al. Preeclampsia-eclampsia:clinical and neuroradiographic correlates and insights into the pathogenesis of hypertensive encephalopathy. Radiology,2000,217(2):371-376.
133. Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature,2004, 429(6990):413-417.
134. Schanzer A, Wachs FP, Wilhelm D, et al. Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol, 2004,14(3):237-248.
135. Kilic U, Kilic E, Jarve A, et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci,2006,26(48):12439-12446.
136. Schanzer A, Wachs FP, Wilhelm D, et al. Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol, 2004,14(3):237-248.
137. Famiglietti EV, Stopa EG, McGookin ED, et al. Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina. Brain Res,2003,969(1-2):195-204.
138. Nishijima K, Ng YS, Zhong L, et al. VEGF-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol,2007,171(1):53-67.
139. Storkebaum E, Lambrechts D, Carmeliet P. VEGF:once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays,2004,26(9): 943-954.
140. Del Bo R, Scarlato M, Ghezzi S, et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol,2005,57(3): 373-380.
141. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet,2003,34(4):383-394.
142. Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci,2005,8(1):85-92.
143. Devos D, Moreau C, Lassalle P, et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology,2004,62(11):2127-2129.
144. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet,2001,28(2):131-138.
145. Horowitz JR, Rivard A, Van ZR, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxidedependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol, 1997,17(11):2793-2800.
146. Lammert E, Gu G, McLaughlin M, et al. Role of VEGF-A in vascularization of pancreatic islets. Curr Biol,2003,13(12):1070-1074.
147. Tuder RM, Zhen L, Cho CY, et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol,2003,29(1):88-97.
148. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest,2003, 111(5):707-716.
149. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFltl) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest,2003,111 (5):649-658.
150. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol,2006,290(2):H547-559.
151. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol, 2006,290(2):H560-576.
152. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema.2000,106(11):1311-1319.
153. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest,2006,116(10):2610-2621.
154. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol,2006,290(2):H547-559.
155. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol,2004, 165(1):35-52.
156. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol, 2006,290 (2):H560-576.
157. Kaner RJ, Ladetto JV, Singh R, et al. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol,2000,22: 657-664.
158. Meyer KC, Cardoni AL, Xiang Z, et al.Vascular endothelial growth factor in human lung transplantation. Chest,2001,119:137-143.
159. Fehrenbach A, Pufe T, Wittwer T, et al. Reduced vascular endothelial growth factor correlates with alveolar epithelial damage after experimental ischemia and reperfusion. J Heart Lung Transplant,2003,22:967-978.
160. Fischer S, Cassivi SD, Xavier AM, et al. Cell death in human lung transplantation: apoptosis induction in human lungs during ischemia and after transplantation. Ann Surg,2000,231:424-431.
161. Kazi AA, Lee WS, Wagner E, et al. VEGF, fetal liver kinase-1, and permeability increase during unilateral lung ischemia. Am J Physiol Lung Cell Mol Physiol,2000, 279:L460-467.
162. Crapo JD. Morphologic changes in pulmonary oxygen toxicity. Annu Rev Physiol, 1986,48:721-731.
163. Ekekezie II, Thibeault DW, Rezaiekhaligh MH, et al. Endostatin and vascular endothelial cell growth factor (VEGF) in piglet lungs:effect of inhaled nitric oxide and hyperoxia. Pediatr Res,2003,53:440-446.
164. Buckley S, Warburton D. Dynamics of metalloproteinase-2 and -9, TGF-beta, and uPA activities during normoxic vs. hyperoxic alveolarization. Am J Physiol Lung Cell Mol Physiol,2002,283:L747-754.
165. Gushima Y, Ichikado K, Suga M, et al. Expression of matrix metalloproteinases in pigs with hyperoxia-induced acute lung injury. Eur Respir J,2001,18:827-837.
166. Slutsky AS, Tremblay LN. Multiple system organ failure:Is mechanical ventilation a contributing factor? Am J Respir Crit Care Med,1998,157:1721-1725.
167. [Anon] Ventilation with lower tidal volumes compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med,2000,342:1301-1308.
168. Ranieri VM, Suter PM, Tortorella C, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome:a randomized controlled trial. JAMA,1999,282:54-61.
169. Wrigge H, Zinserling J, Stuber F, et al. Effects of mechanical ventilation on release of cytokines into systemic circulation in patients with normal pulmonary function. Anesthesiology,2000,93:1413-1417.
170. Gurkan OU, O'Donnell C, Brower R, et al. Differential effects of mechanical ventilatory strategy on lung injury and systemic organ inflammation in mice. Am J Physiol Lung Cell Mol Physiol,2003,285:L710-718.
171. Choi WI, Quinn DA, Park KM, et al. Systemic microvascular leak in an in vivo rat model of ventilator-induced lung injury. Am J Respir Crit Care Med,2003,167: 1627-1632.
172. David RT, Lynne A, Ann-B M. A role for vascular endothelial growth factor in acute and resolving lung injury. Am J Respir Crit Care Med,2002,166:1332-1337.
173. Hidefumi K, Sadatomo T, Naoki H, et al. Vascular endothelial growth factor in epithelial lining fluid of patients with acute respiratory distress syndrome. Respirology,2008,13:281-284.
174. Kaner RJ, Ladetto JV, Singh R, et al. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary oedema. Am J Respir Cell Mol Biol,2000,22: 657-664.
175. Ohwada A, Yoshioka Y, Iwabuchi K, et al. VEGF regulates the proliferation of acid-exposed alveolar lining epithelial cells. Thorax,2003,58:328-332.
176. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature,1993,362:841-844.
177. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res,1997,57:4593-4599.
178. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina,2006,26(5):495-511.
179. Balamurali KA, Miho N, Nirbhai S, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature,2006,443:993-997.
180. Volker Schmitz, Miroslaw Kornek, Tobias Hilbert. Treatment of metastatic colorectal carcinomas by systemic inhibition of vascular endothelial growth factor signaling in mice. World J Gastroenterol,2005,11(28):4332-4336.
181. Kiichiro Y, Patricia CL, Janet MM. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. The Journal of Experimental Medicine, 2006,203:1447-1458.
182. Presta L G, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res,1997,57:4593-4599.
183. Simpson AH, Mills L, Noble B. The role of growth factors and related agents in accelerating fracture healing. J Bone Joint Surg Br,2006,88(6):701-705.
184. Simons M, Ware JA. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov,2003,2(11):863-871.
185. Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease:a phase 2 randomized, controlled trial of AdVEGF(121) versus maximum medical treatment. Gene Ther,2006,13 (21):1503-1511.
186. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med,2002,136(1):54-71.
187. Schratzberger P, Schratzberger G, Silver M, et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med,2000,6(4):405-413.
188. Lee HJ, Kim KS, Park IH, et al. Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model. PLoS ONE,2007,2:e156.
189. Del BR, Scarlato M, Ghezzi S, et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol,2005,57(3): 373-380.
190. Wang Y, Mao XO, Xie L, et al. Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J Neurosci,2007,27(2):304-307.
191. Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature,2004, 429(6990):413-417.
192. Eming SA, Krieg T. Molecular Mechanisms of VEGF-A Action during Tissue Repair. J Invest Dermatol,2006,126(Suppl):79-86.
2. Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med,2004,351: 884-892.
3. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med,2005,353:1685-1693.
4. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science,1989,246:1306-1309.
5. Ferrara N. VEGF:an update on biological and therapeutic aspects. Curr Opin Biotechnol,2000,11(6):617-624.
6. Zebrowski BK, Yano S, Liu W, et al.Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res,1999,5(11): 3364-3368.
7. Schoch HJ, Fischer S, Marti HH. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain,2002,125:2549-2557.
8. Kaner RJ, Ladetto JV, Singh R, et al. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol,2000,22: 657-664.
9. Otani N, Minami S, Yamoto M, et al. The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy. J Clin Endocrinol Metab,1999,84(10):3845-3851.
10. Fraser HM. Regulation of the ovarian follicular vasculature. Reprod Biol Endocrinol, 2006,4(1):18.
11. Koyama S, Sato E, Tsukadaira A, et al. Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro. Eur Respir J,2002,20: 1449-1456.
12. Saint-Geniez M, Maldonado AE, D'Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci,2006,47(7):3135-3142.
13. Ng YS, Rohan R, Sunday ME, et al. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn,2001,220(2):112-121.
14. Bernini GP, Moretti A, Bonadio AG, et al. Angiogenesis in human normal and pathologic adrenal cortex. J Clin Endocrinol Metab,2002,87(11):4961-4965.
15. Maharaj AS, Saint-Geniez M, Maldonado AE, et al. Vascular endothelial growth factor localization in the adult. Am J Pathol,2006,168(2):639-648.
16. Taichman NS, Cruchley AT, Fletcher LM, et al. Vascular endothelial growth factor in normal human salivary glands and saliva:a possible role in the maintenance of mucosal homeostasis. Lab Invest,1998,78(7):869-875.
17. Katoh R. Angiogenesis in endocrine glands:special reference to the expression of vascular endothelial growth factor. Microsc Res Tech,2003,60(2):181-185.
18. Acker T, Beck H, Plate KH. Cell type specific expression of vascular endothelial growth factor and angiopoietin-1 and -2 suggests an important role of astrocytes in cerebellar vascularization. Mech Dev,2001,108(1-2):45-57.
19. Storkebaum E, Lambrechts D, Carmeliet P. VEGF:once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays,2004,26(9):943-954.
20. Del BR, Scarlato M, Ghezzi S, et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol,2005,57(3):373-380.
21. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet,2003,34(4):383-394.
22. Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci,2005,8(1):85-92.
23. Devos D, Moreau C, Lassalle P, et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology,2004,62(11):2127-2129.
24. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet,2001,28(2):131-138.
25. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res,1997,57:4593-4599.
26. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina,2006,26(5):495-511.
27. Berse B, Brown LF, Van-de WL, et al. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumours. Mol Biol Cell,1992,3:211-220.
28. Koyama S, Sato E, Tsukadaira A, et al. Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro. Eur Respir J,2002,20: 1449-1456.
29. Boussat S, Eddahibi S, Coste A, et al. Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol,2000,279:L371-378.
30. Kaner RJ, Crystal RG. Compartmentalization of vascular endothelial growth factor to the epithelial surface of the human lung. Mol Med,2001,7:240-246.
31. Fehrenbach A, Pufe T, Wittwer T, et al. Reduced vascular endothelial growth factor correlates with alveolar epithelial damage after experimental ischemia and reperfusion. J Heart Lung Transplant,2003,22:967-978.
32. Asai K, Kanazawa H, Kamoi H, et al. Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin Exp Allergy,2003,33(5):595-599.
33. Chetta A, Zanini A, Foresi A, et al. Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma. Clin Exp Allergy,2005,35(11):1437-1442.
34. Hoshino M, Nakamura Y, Hamid QA. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol, 2001,107(6):1034-1038.
35. Kanazawa H, Hirata K, Yoshikawa J. Involvement of vascular endothelial growth factor in exercise induced bronchoconstriction in asthmatic patients. Thorax,2002,57(10): 885-888.
36. Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways andits relationship to angiogenesis. J Allergy Clin Immunol,2001,107(2):295-301.
37. Feltis BN, Wignarajah D, Zheng L, et al. Increased vascular endothelial growth factor and receptors:relationship to angiogenesis in asthma. Am J Respir Crit Care Med,2006, 173(11):1201-1207.
38. Asai K, Kanazawa H, Otani K, et al. Imbalance between vascular endothelial growth factor and endostatin levels in induced sputum from asthmatic subjects. J Allergy Clin Immunol,2002,110(4):571-575.
39. Kishiro I, Kato S, Fuse D, et al. Clinical significance of vascular endothelial growth factor in patients with primary lung cancer. Respirology,2002,7(2):93-98.
40. Cressey R, Wattananupong O, Lertprasertsuke N, et al. Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis. BMC Cancer,2005,5:128-136.
41. Kiropoulos TS, Kostikas K, Gourgoulianis KI. Vascular endothelial growth factor levels in pleural fluid and serum of patients with tuberculous pleural effusions. Chest,2005, 128(1):468-469.
42. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer,1999,85(1): 178-187.
1. Bernard GR, Artigas A, Brigham KL, et al. Report of the American-European Consensus Conference on acute respiratory distress syndrome:definitions, mechanisms, relevant outcomes, and clinical trial coordination. J Crit Care,1994,9: 72-81.
2. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med,2005,353:1685-1693.
3. Faridy EE, Permutt S, Riley RL. Effect of ventilation on surface forces in excised dogs'lungs. J Appl Physiol,1966,21:1453-1462.
4. Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med,2004, 351:884-892.
5. Ferrara N. VEGF:an update on biological and therapeutic aspects. Curr Opin Biotechnol,2000,11(6):617-624.
6. Zebrowski BK, Yano S, Liu W, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res,1999,5(11): 3364-3368.
7. Masood R, Cai J, Zheng T, et al. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci USA,1997,94(3):979-984.
8. Balamurali KA, Miho N, Nirbhai S, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature,2006,443:993-997.
9. Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol,2006,290(2):L209-221.
10. Medford AR, Millar AB. Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS):paradox or paradigm? Thorax,2006,61(7):621-626.
11. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med, 2003,9:669-676.
12. Poltorak Z, Cohen T, Neufeld G. The VEGF splice variants:properties, receptors, and usage for the treatment of ischemic diseases. Herz,2000,25:126-129.
13. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci,2001,114:853-865.
14. Nagase T, Uozumi N, Ishii S, et al. Acute lung injury by sepsis and acid aspiration:a key role for cytosolic phospholipase A2. Nat Immunol,2000,1(1):42-46.
15. Zheng CH, Gao JQ, Zhang YP, et al. A protein delivery system:biodegradable alginate-chitosan-poly (lactic-co-glycolic acid) composite microspheres. Biochem Biophys Res Commun,2004,323(4):1321-1327.
16. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science,1989,246 (4935):1309-1312.
17. Yang SP, Bae DG, Kang HJ, et al. Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging,2004,25(3):283-290.
18. Michael WP. A new mathematical model for relative quantification in real- time RT-PCR. Nucleic Acids Res,2001,29 (9):2002-2007.
19. Ashbaugh DG, Bigelow DB, Petty TL, et al. Acute respiratory distress syndrome. Lancet,1967,2:319-323.
20. Po-Nien T, Feng-Tsan C, Shu-Chen W, et al. Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis. Crit Care Med,2007,35:1955-1960.
21. Rocco PR, Zin WA. Pulmonary and extrapulmonary acute respiratory distress syndrome:are they different? Curr Opin Crit Care,2005,11(1):10-17.
22. Pelosi PD, Onofrio D, Chiumello D. Pulmonary and extrapulmonary acute respiratory distress syndrome are different. Eur Respir J,2003,22:48-56.
23. Hoelz C, Negri EM, Lichtenfels AJ, et al. Morphometric differences in pulmonary
lesions in primary and secondary ARDS:a preliminary study in autopsies. Pathol Res Pract,2001,197:521-530.
24. Berse B, Brown LF, Van-de WL, et al. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumours. Mol Biol Cell,1992,3:211-220.
25. Koyama S, Sato E, Tsukadaira A, et al. Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro. Eur Respir J,2002,20: 1449-1456.
26. Boussat S, Eddahibi S, Coste A, et al. Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol,2000,279:L371-378.
27. Kaner RJ, Crystal RG. Compartmentalization of vascular endothelial growth factor to the epithelial surface of the human lung. Mol Med,2001,7:240-246.
28. Marco M, Claudia CS, Duncan S, et al. Vascular endothelial growth factor and related molecules in acute lung injury. J Appl Physiol,2004,97:1605-1617.
1. Tsao PN, Chan FT, Wei SC, et al. Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis. Crit Care Med,2007,35:1955-1960.
2. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA,1993,90: 10705-10709.
3. Nagase T, Uozumi N, Ishii S, et al. Acute lung injury by sepsis and acid aspiration:a key role for cytosolic phospholipase A2. Nat Immunol,2000,1(1):42-46.
4. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science,1989,246 (4935):1309-1312.
5. Zheng CH, Gao JQ, Zhang YP, et al. A protein delivery system:biodegradable alginate-chitosan-poly (lactic-co-glycolic acid) composite microspheres. Biochem Biophys Res Commun,2004,323(4):1321-1327.
6. Yang SP, Bae DG, Kang HJ, et al. Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol Aging,2004,25(3):283-290.
7. Michael WP. A new mathematical model for relative quantification in real- time RT-PCR. Nucleic Acids Res,2001,29 (9):2002-2007.
8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med, 2003,9:669-676.
9. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J Biol Chem,1994,269:26988-26995.
10. Seetharam L, Gotoh N, Maru Y, et al. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene,1995,10: 135-147.
11. Terman BI, Dougher VM, Carrion ME, et al. Identification of the KDR tyrosine kinase
as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun,1992,187:1579-1586.
12. Barleon B, Hauser S, Schollmann C, et al. Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells. J Cell Biochem,1994, 54:56-66.
13. Charnock-Jones DS, Sharkey AM, Boocock CA, et al. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. Biol Reprod,1994,51:524-530.
14. Fehrenbach H, Haase M, Kasper M, et al. Alterations in the immunohistochemical distribution patterns of vascular endothelial growth factor receptors Flkl and Fltl in bleomycin-induced rat lung fibrosis. Virchows Arch,1999,435:20-31.
15. Brown KR, England KM, Goss KL, et al. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol,2001, 281:L1001-1010.
16. Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature,1995,376:66-70.
17. Fong GH, Zhang L, Bryce DM, et al. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development, 1999,126:3015-3025.
18. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood,1996,87:3336-3343.
19. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J,1996,15:290-298.
20. Lee J, Gray A, Yuan J, et al. Vascular endothelial growth factor-related protein:a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA,1996,93:1988-1992.
21. Balamurali KA, Miho N, Nirbhai S, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature,2006,443:993-997.
22. Volker Schmitz, Miroslaw Kornek, Tobias Hilbert. Treatment of metastatic colorectal carcinomas by systemic inhibition of vascular endothelial growth factor signaling in mice. World J Gastroenterol,2005,11(28):4332-4336.
23. Kiichiro Y, Patricia CL, Janet MM. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. The Journal of Experimental Medicine, 2006,203:1447-1458.
1. Kaner RJ, Ladetto JV, Singh R, et al. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary oedema. Am J Respir Cell Mol Biol,2000,22: 657-664.
2. Bardales RH, Hailey LS, Xie SS, et al. In situ apoptosis assay for the detection of early acute myocardial infarction. Am J Pathol,1996,149:821-829.
3. Wijsman JH, Jonker RR, Keijzer R, et al. A new method to detect apoptosis in paraffin sections:in situ end-labeling of fragmented DNA. The Journal of Histochemistry and Cytochemistry,1993,41:7-12.
4. Schneeberger EE, Lynch RD. Structure, function, and regulation of cellular tight junctions. Am J Physiol,1992,262(6):L647-661.
5. Michael WP. A new mathematical model for relative quantification in real- time RT-PCR. Nucleic Acids Res,2001,29 (9):2002-2007.
6. Alavi A, Hood JD, Frausto R, et al. Role of raf in vascular protection from distinct apoptotic stimuli. Science,2003,301:94-96.
7. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science,1989,246:1306-1309.
8. Ferrara N. VEGF:an update on biological and therapeutic aspects. Curr Opin Biotechnol,2000,11(6):617-624.
9. Zebrowski BK, Yano S, Liu W, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res,1999,5(11): 3364-3368.
10. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem, 1998,273:13313-13316.
11. Berthiaume Y, Hans GF, Michael AM. Lung Edema Clearance:20 years of progress invited review:alveolar edema fluid clearance in the injured lung. J Appl Physiol,2002,
93:2207-2213.
12. Bern RA, Bos AP, Matute-Bello G, et al. Lung epithelial cell apoptosis during acute lung injury in infancy. Pediatr Crit Care Med,2007,8:132-137.
13. Hans-Peter G, Vishva D, Napoleone F. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl2 and Al in vascular endothelial cells. J Biol Chem,1998,273:13313-13316.
14. Mishra DP, Dhali A. Endotoxin induces luteal cell apoptosis through the mitochondrial pathway. Epub,2007,83(1-2):75-88.
15. Kiichiro Y, Patricia CL, Janet MM, et al. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med,2006,203: 1447-1458.
16. Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF-2 alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med,2002,8:702-710.
17. Brown KR, England KM, Goss KL, et al. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol,2001, 281:L1001-1010.
18. Fehrenbach H, Haase M, Kasper M, et al. Alterations in the immunohistochemical distribution patterns of vascular endothelial growth factor receptors Flkl and Fltl in bleomycin-induced rat lung fibrosis. Virchows Arch,1999,435:20-31.
1. Ferrara N. VEGF:an update on biological and therapeutic aspects. Curr Opin Biotechnol,2000,11(6):617-624.
2. Zebrowski BK, Yano S, Liu W, et al.Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res,1999, 5(11):3364-3368.
3. Miquerol L, Gertsenstein M, Harpal K, et al. Multiple developmental roles of VEGF suggested by a LacZ-tagged allele. Dev Biol,1999,212(2):307-322.
4. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun, 1989,161(2):851-858.
5. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature,1996,380(6573):439-442.
6. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature,1996,380(6573):435-439.
7. Miquerol L, Langille BL, Nagy A. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development, 2000,127 (18):3941-3946.
8. Bates DO, Hillman NJ, Williams B, et al. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat,2002,200:581-597.
9. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1995,1(1):27-31.
10. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature,2000, 407(6801):249-257.
11. Moreno PR, Purushothaman KR, Sirol M, et al. Neovascularization in human atherosclerosis. Circulation,2006,113 (18):2245-2252.
12. Yano K, Liaw PC, Mullington JM, et al. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med,2006,203 (6): 1447-1458.
13. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science,1989,246:1306-1309.
14. Napoleone F, Hans-Peter G, Jennifer L. The biology of VEGF and its receptors. Nature,2003,9:669-676.
15. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and Al in vascular endothelial cells. J Biol Chem, 1998,273:13313-13316.
16. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med, 2003,9:669-676.
17. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science,1983,219(4587): 983-985.
18. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res,2001,49(3): 568-581.
19. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J Biol Chem,1994,269:26988-26995.
20. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med, 2003,9:669-676.
21. Poltorak Z, Cohen T, Neufeld G. The VEGF splice variants:properties, receptors, and usage for the treatment of ischemic diseases. Herz,2000,25:126-129.
22. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci,2001,114:853-865.
23. Olofsson B, Pajusola K, Kaipainen A, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA,1996,93: 2576-2581.
24. Wanstall JC, Gambino A, Jeffery TK, et al. Vascular endothelial growth factor-B deficient mice show impaired development of hypoxic pulmonary hypertension. Cardiovasc Res,2002,55:361-368.
25. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science,1997,276:1423-1425.
26. Cao R, Eriksson A, Kubo H, et al. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res,2004,94:664-670.
27. Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med,2002, 196:1497-1506.
28. Paavonen K, Mandelin J, Partanen T, et al. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium. J Rheumatol,2002,29:39-45.
29. Skobe M, Hamberg LM, Hawighorst T, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol,2001,159:893-903.
30. Autiero M, Waltenberger J, Communi D, et al. Role of P1GF in the intra- and intermolecular cross talk between the VEGF receptors Fltl and Flkl. Nat Med,2003, 9:936-943.
31. Cao Y, Chen H, Zhou L, et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem,1996,271:3154-3162.
32. Hauser S, Weich HA. A heparin-binding form of placenta growth factor (P1GF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors, 1993,9:259-268.
33. Persico MG, Vincenti V, Dipalma T. Structure, expression and receptor-binding properties of placenta growth factor (P1GF). Curr Top Microbiol Immunol,1999,237: 31-40.
34. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med,2001,7:575-583.
35. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med, 2003,9:669-676.
36. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J Biol Chem,1994,269:26988-26995.
37. Seetharam L, Gotoh N, Maru Y, et al. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene,1995,10: 135-147.
38. Terman BI, Dougher VM, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun,1992,187:1579-1586.
39. Barleon B, Hauser S, Schollmann C, et al. Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells. J Cell Biochem, 1994,54:56-66.
40. Charnock-Jones DS, Sharkey AM, Boocock CA, et al. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. Biol Reprod,1994,51:524-530.
41. Fehrenbach H, Haase M, Kasper M, et al. Alterations in the immunohistochemical distribution patterns of vascular endothelial growth factor receptors Flkl and Fltl in bleomycin-induced rat lung fibrosis. Virchows Arch,1999,435:20-31.
42. Brown KR, England KM, Goss KL, et al. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol,2001, 281:L1001-1010.
43. Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature,1995,376:66-70.
44. Fong GH, Zhang L, Bryce DM, et al. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development, 1999,126:3015-3025.
45. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood,1996,87:3336-3343.
46. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J,1996,15:290-298.
47. Lee J, Gray A, Yuan J, et al. Vascular endothelial growth factor-related protein:a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA,1996,93:1988-1992.
48. Baldwin ME, Catimel B, Nice EC, et al. The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man. J Biol Chem, 2001,276:19166-19171.
49. Lymboussaki A, Partanen TA, Olofsson B, et al. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol,1998,153:395-403.
50. Meyer M, Clauss M, Lepple-Wienhues A, et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signaling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J,1999, 18:363-374.
51. Ogawa S, Oku A, Sawano A, et al. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem,1998,273: 31273-31282.
52. Park JE, Chen HH, Winer J, et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem,1994,269:25646-25654.
53. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev, 2002,82:673-700.
54. Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA,1998,95:11709-11714.
55. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J,1996,15:290-298.
56. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J Biol Chem,1994,269:26988-26995.
57. Stevens A, Soden J, Brenchley PE, et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res,2003,63: 812-816.
58. Otani N, Minami S, Yamoto M et al. The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy. J Clin Endocrinol Metab,1999,84(10):3845-3851.
59. Fraser HM. Regulation of the ovarian follicular vasculature. Reprod Biol Endocrinol, 2006,4(1):18.
60. Berse B, Brown LF, Van-de WL, et al. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumours. Mol Biol Cell,1992,3:211-220.
61. Koyama S, Sato E, Tsukadaira A, et al. Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro. Eur Respir J,2002,20: 1449-1456.
62. Boussat S, Eddahibi S, Coste A, et al. Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol,2000,279:L371-378.
63. Saint-Geniez M, Maldonado AE, D'Amore PA. VEGF expression and receptor activation in the choroid during development and in the adult. Invest Ophthalmol Vis Sci,2006,47(7):3135-3142.
64. Ng YS, Rohan R, Sunday ME, et al. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn,2001,220(2):112-121.
65. Pammer J, Weninger W, Mildner M, et al. Vascular endothelial growth factor is constitutively expressed in normal human salivary glands and is secreted in the saliva of healthy individuals. J Pathol,1998,186 (2):186-191.
66. Bernini GP, Moretti A, Bonadio AG, et al. Angiogenesis in human normal and pathologic adrenal cortex. J Clin Endocrinol Metab,2002,87(11):4961-4965.
67. Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci USA,1998, 95(26):15809-15814.
68. Maharaj AS, Saint-Geniez M, Maldonado AE, et al. Vascular endothelial growth factor localization in the adult. Am J Pathol,2006,168(2):639-648.
69. Taichman NS, Cruchley AT, Fletcher LM, et al. Vascular endothelial growth factor in normal human salivary glands and saliva:a possible role in the maintenance of mucosal homeostasis. Lab Invest,1998,78(7):869-875.
70. Katoh R. Angiogenesis in endocrine glands:special reference to the expression of vascular endothelial growth factor. Microsc Res Tech,2003,60(2):181-185.
71. Monacci WT, Merrill MJ, Oldfield EH. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol,1993, 264:995-1002.
72. Acker T, Beck H, Plate KH. Cell type specific expression of vascular endothelial growth factor and angiopoietin-1 and -2 suggests an important role of astrocytes in cerebellar vascularization. Mech Dev,2001,108(1-2):45-57.
73. Witmer AN, Dai J, Weich HA, et al. Expression of vascular endothelial growth factor receptors 1,2, and 3 in quiescent endothelia. J Histochem Cytochem,2002,50(6): 767-777.
74. Yang SZ, Zhang LM, Huang YL, et al. Distribution of Flk-1 and Flt-1 receptors in neonatal and adult rat brains. Anat Rec A Discov Mol Cell Evol Biol,2003,274(1): 851-856.
75. Lee JW, Bae SH, Jeong JW, et al. Hypoxiainducible factor (HEF-1) alpha:its protein stability and biological functions. Exp Mol Med,2004,36:1-12.
76. Semenza GL, Agani F, Feldser D, et al. Hypoxia, HIF-1, and the pathophysiology of common human diseases. Adv Exp Med Biol,2000,475:123-130.
77. Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci USA,1998, 95:15809-15814.
78. Liu Y, Cox SR, Morita T, et al. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5 enhancer. Circ Res,1995, 77:638-643.
79. Chua CC, Hamdy RC, Chua BH. Upregulation of vascular endothelial growth factor by H2O2 in rat heart endothelial cells. Free Radic Biol Med,1998,25:891-897.
80. Shweiki D, Neeman M, Itin A, et al. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids:implications for tumor angiogenesis. Proc Natl Acad Sci USA,1995,92:768-772.
81. Howdieshell TR, Webb WL, Sathyanarayana, et al. Inhibition of inducible nitric oxide synthase results in reductions in wound vascular endothelial growth factor expression, granulation tissue formation, and local perfusion. Surgery,2003,133: 528-537.
82. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest,1995,95:1798-1807.
83. Boussat S, Eddahibi S, Coste A, et al. Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol,2000,279:L371-378.
84. Cohen T, Nahari D, Cerem LW, et al. Interleukin-6 induces the expression of vascular endothelial growth factor. J Biol Chem,1996,271:736-741.
85. Frank S, Hubner G, Breier G, et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem,1995,270:12607-12613.
86. Yan SF, Tritto I, Pinsky D, et al. Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6. J Biol Chem, 1995,270:11463-11471.
87. Koyama S, Sato E, Tsukadaira A, et al. Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro. Eur Respir J,2002,20: 1449-1456.
88. Trompezinski S, Denis A, Vinche A, et al. IL-4 and interferon-gamma differentially modulate vascular endothelial growth factor release from normal human keratinocytes and fibroblasts. Exp Dermatol,2002,11:224-231.
89. Wen FQ, Liu X, Manda W, et al. TH2 cytokine-enhanced and TGF-beta-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids. J Allergy Clin Immunol,2003,111:1307-1318.
90. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood,1996,87:3336-3343.
91. Becker PM, Verin AD, Booth MA, et al. Differential regulation of diverse physiological responses to VEGF in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol,2001,281:L1500-1511.
92. Becker PM, Alcasabas A, Yu AY, et al. Oxygen-independent upregulation of vascular endothelial growth factor and vascular barrier dysfunction during ventilated pulmonary ischemia in isolated ferret lungs. Am J Respir Cell Mol Biol,2000,22: 272-279.
93. Harada SI, Nagy JA, Sullivan KA, et al. Induction of vascular endothelial growth factor expression by prostaglandin E2 and El in osteoblasts. Clin Invest,1994,93: 2490-2496.
94. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature,1996,380:439-442.
95. Breier G, Damert A, Plate KH, et al. Angiogenesis in embryos and ischemic diseases. Thromb Haemost,1997,78:678-683.
96. Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci USA,1998, 95:15809-15814.
97. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature,1995,376:62-66.
98. Alavi A, Hood JD, Frausto R, et al. Role of raf in vascular protection from distinct apoptotic stimuli. Science,2003,301:94-96.
99. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3-kinase/Akt signal transduction pathway, requirement for Flk-1/KDR activation. J Biol Chem, 1998,273:30336-30343.
100. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem, 1998,273:13313-13316.
101. Tsao PN, Su YN, Li H, et al. Overexpression of placenta growth factor contributes to the pathogenesis of pulmonary emphysema. Am J Respir Crit Care Med,2004,169: 505-511.
102. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science,1989,246:1306-1309.
103. Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF-2 alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med,2002,8:702-710.
104. Brown KR, England KM, Goss KL, et al. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol,2001, 281:L1001-1010.
105. Duyndam MC, Hilhorst MC, Schluper HM, et al. Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol,2002,160 (2):537-548.
106. Clauss M, Weich H, Breier G, et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem,1996,271 (30): 17629-17634.
107. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood,1996,87(8):3336-3343.
108. Norrby K. Mast cells and angiogenesis. Apmis,2002,110(5):355-371.
109. Dikov MM, Ohm JE, Ray N, et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol,2005,174(1): 215-222.
110. Feistritzer C, Kaneider NC, Sturn DH et al. Expression and function of the vascular endothelial growth factor receptor FLT-1 in human eosinophils. Am J Respir Cell Mol Biol,2004,30(5):729-735.
111. Shui YB, Wang X, Hu JS, et al. Vascular endothelial growth factor expression and signaling in the lens. Invest Ophthalmol Vis Sci,2003,44 (9):3911-3919.
112. Casella I, Feccia T, Chelucci C, et al. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Fltl receptor. Blood,2003,101(4): 1316-1323.
113. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell,2006,124(1):175-189.
114. Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature,2002,417(6892):954-958.
115. Murayama T, Tepper OM, Silver M, et al. Determination of bone marrow-derived endothelial progenitor cell significance in angiogenic growth factor-induced neovascularization in vivo. Exp Hematol,2002,30(8):967-972.
116. Iwaguro H, Yamaguchi J, Kalka C, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation,2002, 105(6):732-738.
117. Farahani M, Treweeke AT, Toh CH, et al. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia,2005,19(4):524-530.
118. Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med,2002,8(7):702-710.
119. Esser S, Wolburg K, Wolburg H, et al. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol,1998,140(4):947-959.
120. Eming SA, Krieg T. Molecular mechanisms of VEGF-A action during tissue repair. J Invest Dermatol,2006,126:79-86.
121. Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling- in control of vascular function. Nat Rev Mol Cell Biol,2006,7(5):359-371.
122. Maharaj AS, Saint-Geniez M, Maldonado AE, et al. Vascular endothelial growth factor localization in the adult. Am J Pathol,2006,168(2):639-648.
123. Bates DO, Hillman NJ, Williams B, et al. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat,2002,200(6):581-597.
124. Schoch HJ, Fischer S, Marti HH. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain,2002,125:2549-2557.
125. Kaner RJ, Ladetto JV, Singh R, et al. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol,2000,22: 657-664.
126. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood,1996,87:3336-3343.
127. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev, 2002,82:673-700.
128. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet,2005,365(9461): 785-799.
129. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med,2004,350(7):672-683.
130. McKeeman GC, Ardill JE, Caldwell CM, et al. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol,2004,191(4):1240-1246.
131. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFltl) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest,2003,111(5):649-658.
132. Schwartz RB, Feske SK, Polak JF, et al. Preeclampsia-eclampsia:clinical and neuroradiographic correlates and insights into the pathogenesis of hypertensive encephalopathy. Radiology,2000,217(2):371-376.
133. Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature,2004, 429(6990):413-417.
134. Schanzer A, Wachs FP, Wilhelm D, et al. Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol, 2004,14(3):237-248.
135. Kilic U, Kilic E, Jarve A, et al. Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci,2006,26(48):12439-12446.
136. Schanzer A, Wachs FP, Wilhelm D, et al. Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol, 2004,14(3):237-248.
137. Famiglietti EV, Stopa EG, McGookin ED, et al. Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina. Brain Res,2003,969(1-2):195-204.
138. Nishijima K, Ng YS, Zhong L, et al. VEGF-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol,2007,171(1):53-67.
139. Storkebaum E, Lambrechts D, Carmeliet P. VEGF:once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays,2004,26(9): 943-954.
140. Del Bo R, Scarlato M, Ghezzi S, et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol,2005,57(3): 373-380.
141. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet,2003,34(4):383-394.
142. Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci,2005,8(1):85-92.
143. Devos D, Moreau C, Lassalle P, et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology,2004,62(11):2127-2129.
144. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet,2001,28(2):131-138.
145. Horowitz JR, Rivard A, Van ZR, et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxidedependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol, 1997,17(11):2793-2800.
146. Lammert E, Gu G, McLaughlin M, et al. Role of VEGF-A in vascularization of pancreatic islets. Curr Biol,2003,13(12):1070-1074.
147. Tuder RM, Zhen L, Cho CY, et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol,2003,29(1):88-97.
148. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest,2003, 111(5):707-716.
149. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFltl) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest,2003,111 (5):649-658.
150. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol,2006,290(2):H547-559.
151. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol, 2006,290(2):H560-576.
152. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema.2000,106(11):1311-1319.
153. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest,2006,116(10):2610-2621.
154. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol,2006,290(2):H547-559.
155. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol,2004, 165(1):35-52.
156. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol, 2006,290 (2):H560-576.
157. Kaner RJ, Ladetto JV, Singh R, et al. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol,2000,22: 657-664.
158. Meyer KC, Cardoni AL, Xiang Z, et al.Vascular endothelial growth factor in human lung transplantation. Chest,2001,119:137-143.
159. Fehrenbach A, Pufe T, Wittwer T, et al. Reduced vascular endothelial growth factor correlates with alveolar epithelial damage after experimental ischemia and reperfusion. J Heart Lung Transplant,2003,22:967-978.
160. Fischer S, Cassivi SD, Xavier AM, et al. Cell death in human lung transplantation: apoptosis induction in human lungs during ischemia and after transplantation. Ann Surg,2000,231:424-431.
161. Kazi AA, Lee WS, Wagner E, et al. VEGF, fetal liver kinase-1, and permeability increase during unilateral lung ischemia. Am J Physiol Lung Cell Mol Physiol,2000, 279:L460-467.
162. Crapo JD. Morphologic changes in pulmonary oxygen toxicity. Annu Rev Physiol, 1986,48:721-731.
163. Ekekezie II, Thibeault DW, Rezaiekhaligh MH, et al. Endostatin and vascular endothelial cell growth factor (VEGF) in piglet lungs:effect of inhaled nitric oxide and hyperoxia. Pediatr Res,2003,53:440-446.
164. Buckley S, Warburton D. Dynamics of metalloproteinase-2 and -9, TGF-beta, and uPA activities during normoxic vs. hyperoxic alveolarization. Am J Physiol Lung Cell Mol Physiol,2002,283:L747-754.
165. Gushima Y, Ichikado K, Suga M, et al. Expression of matrix metalloproteinases in pigs with hyperoxia-induced acute lung injury. Eur Respir J,2001,18:827-837.
166. Slutsky AS, Tremblay LN. Multiple system organ failure:Is mechanical ventilation a contributing factor? Am J Respir Crit Care Med,1998,157:1721-1725.
167. [Anon] Ventilation with lower tidal volumes compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med,2000,342:1301-1308.
168. Ranieri VM, Suter PM, Tortorella C, et al. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome:a randomized controlled trial. JAMA,1999,282:54-61.
169. Wrigge H, Zinserling J, Stuber F, et al. Effects of mechanical ventilation on release of cytokines into systemic circulation in patients with normal pulmonary function. Anesthesiology,2000,93:1413-1417.
170. Gurkan OU, O'Donnell C, Brower R, et al. Differential effects of mechanical ventilatory strategy on lung injury and systemic organ inflammation in mice. Am J Physiol Lung Cell Mol Physiol,2003,285:L710-718.
171. Choi WI, Quinn DA, Park KM, et al. Systemic microvascular leak in an in vivo rat model of ventilator-induced lung injury. Am J Respir Crit Care Med,2003,167: 1627-1632.
172. David RT, Lynne A, Ann-B M. A role for vascular endothelial growth factor in acute and resolving lung injury. Am J Respir Crit Care Med,2002,166:1332-1337.
173. Hidefumi K, Sadatomo T, Naoki H, et al. Vascular endothelial growth factor in epithelial lining fluid of patients with acute respiratory distress syndrome. Respirology,2008,13:281-284.
174. Kaner RJ, Ladetto JV, Singh R, et al. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary oedema. Am J Respir Cell Mol Biol,2000,22: 657-664.
175. Ohwada A, Yoshioka Y, Iwabuchi K, et al. VEGF regulates the proliferation of acid-exposed alveolar lining epithelial cells. Thorax,2003,58:328-332.
176. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature,1993,362:841-844.
177. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res,1997,57:4593-4599.
178. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina,2006,26(5):495-511.
179. Balamurali KA, Miho N, Nirbhai S, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature,2006,443:993-997.
180. Volker Schmitz, Miroslaw Kornek, Tobias Hilbert. Treatment of metastatic colorectal carcinomas by systemic inhibition of vascular endothelial growth factor signaling in mice. World J Gastroenterol,2005,11(28):4332-4336.
181. Kiichiro Y, Patricia CL, Janet MM. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. The Journal of Experimental Medicine, 2006,203:1447-1458.
182. Presta L G, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res,1997,57:4593-4599.
183. Simpson AH, Mills L, Noble B. The role of growth factors and related agents in accelerating fracture healing. J Bone Joint Surg Br,2006,88(6):701-705.
184. Simons M, Ware JA. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov,2003,2(11):863-871.
185. Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease:a phase 2 randomized, controlled trial of AdVEGF(121) versus maximum medical treatment. Gene Ther,2006,13 (21):1503-1511.
186. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med,2002,136(1):54-71.
187. Schratzberger P, Schratzberger G, Silver M, et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med,2000,6(4):405-413.
188. Lee HJ, Kim KS, Park IH, et al. Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model. PLoS ONE,2007,2:e156.
189. Del BR, Scarlato M, Ghezzi S, et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol,2005,57(3): 373-380.
190. Wang Y, Mao XO, Xie L, et al. Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J Neurosci,2007,27(2):304-307.
191. Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature,2004, 429(6990):413-417.
192. Eming SA, Krieg T. Molecular Mechanisms of VEGF-A Action during Tissue Repair. J Invest Dermatol,2006,126(Suppl):79-86.